- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07946289
Interleukin-1 Inhibition to Improve the Response of Myeloproliferative Neoplasms Resistant to Cytoreductive Treatment (INTEREST)
Myeloproliferative neoplasms (MPNs) - polycythemia vera, essential thrombocythemia, and primary myelofibrosis - are characterized by excessive myeloid proliferation driven by mutations affecting the JAK2, CALR, and MPL genes, resulting in constitutive activation of hematopoietic cytokine signaling pathways. These hematological malignancies carry an increased risk of thrombosis and may evolve toward secondary myelofibrosis or acute leukemia. Bone marrow inflammation, particularly through interleukin-1 (IL-1), plays a major role in clonal expansion and the clinical expression of these diseases, as demonstrated by preclinical models showing the beneficial effect of its inhibition.
Anakinra, an IL-1 receptor antagonist widely used in rheumatology but never evaluated in MPNs, represents a promising therapeutic option. This proof-of-concept study will randomize 50 patients with a suboptimal response to cytoreductive therapy into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or cytoreductive therapy alone (n=25). The primary endpoint will be the reduction in serum calprotectin levels, a key inflammatory marker of the IL-1 loop that has recently demonstrated prognostic relevance in MPNs. Secondary endpoints will include improvements in hematological parameters, driver mutation allelic burden, pro-inflammatory cytokines, and quality of life.
This study represents an essential step toward larger trials aimed at demonstrating a durable reduction in thrombotic risk and disease progression.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Eligible patients will be identified during routine follow-up visits. After signature of informed consent and confirmation of all eligibility criteria - including a negative urine pregnancy test for women of childbearing potential - patients will be randomized into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or ongoing cytoreductive therapy alone (n=25), for a duration of 3 months.
Clinical and laboratory assessments (CBC, CRP, circulating CD34+ cells, allelic burden, calprotectin, cytokines, quality of life) will be performed at baseline, at 3 months, and at 6 months. An additional visit at 1 month is planned in the anakinra arm to assess tolerability. Patients may withdraw at any time, with reasons documented in the eCRF.
The addition of an anti-IL-1 treatment to cytoreductive therapy could improve its efficacy by promoting control of the mutated clone, which is poorly targeted by current cytoreductive agents other than interferon-α, often poorly tolerated. Better clonal control could limit phenotypic progression, reduce thrombotic risk, and improve hematological response, particularly in the megakaryocytic lineage.
The impact on myelofibrosis, observed in mice, and the improvement in quality of life through reduction of systemic inflammation remain to be confirmed in humans. Not all patients will necessarily benefit from this approach, justifying this exploratory study to evaluate its potential and feasibility.
The risks associated with anakinra are predictable and well documented (local reactions, minor systemic effects, infectious risk), mitigated by the short treatment duration and close monitoring. The benefit-risk ratio is considered favorable.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Eric LIPPERT, Pr
- Telefoonnummer: 0229247037
- E-mail: eric.lippert@chu-brest.fr
Studie Locaties
-
-
-
Angers, Frankrijk, 49000
- Chu Angers
-
Contact:
- Françoise BOYER, Dr
- E-mail: Frboyer@chu-angers.fr
-
Brest, Frankrijk, 29200
- CHU de Brest
-
Contact:
- Jean-Christophe IANOTTO, Pr
- Telefoonnummer: 02 98 22 33 15
- E-mail: jean-christophe.ianotto@chu-brest.fr
-
Morlaix, Frankrijk, 29600
- Ch Pays de Morlaix
-
Contact:
- Christophe NICOL, Dr
- Telefoonnummer: 02 98 62 60 38
- E-mail: Cnicol@ch-morlaix.fr
-
Paris, Frankrijk, 75475
- APHP
-
Contact:
- Jean-Jacques KILADJIAN, Pr
- Telefoonnummer: 01 42 49 94 18
- E-mail: jean-jacques.kiladjian@aphp.fr
-
Tours, Frankrijk, 37044
- Chu Tours
-
Contact:
- Antoine MACHET, Dr
- Telefoonnummer: 02 47 47 37 12
- E-mail: A.machet@chu-tours.fr
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Diagnosis of MPN: PV, ET, or PMF according to WHO criteria
- Stable cytoreductive therapy for at least 6 months
- Incomplete hematologic response according to ELN criteria, excluding bone marrow, OR complete hematologic response with anemia in ET, OR persistence of general clinical symptoms (fever, night sweats, pruritus, fatigue > 5/10 on VAS)
- Adult patient capable of providing informed consent
Exclusion Criteria:
- Recurrent or poorly controlled infections
- Thrombocytopenia < 100 G/L
- Neutropenia < 1 G/L
- Hypersensitivity to the active substance, any excipients, or proteins derived from Escherichia coli
- Concomitant immunosuppressive therapy
- Refusal to participate
- Patient under legal protection (guardianship, curatorship, etc.)
- Patients unable to consent.
- Positive urine pregnancy test at screening / pregnant or breastfeeding women.
- Lack of understanding of questionnaires or inability to follow up.
- Women of childbearing potential unwilling to use a highly effective contraceptive methods
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Anakinra + cytoreductive therapy
Anakinra 100 mg/day subcutaneously for 3 months, added to ongoing standard cytoreductive therapy (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. Additional Month 1 safety/tolerability visit (clinical exam, routine biology, AE/SAE and injection-site reaction review, compliance check) and an injection diary for adherence. |
Recombinant human interleukin-1 receptor antagonist (Kineret 100 mg/0.67 mL prefilled syringe). Administered at 100 mg once daily by subcutaneous injection for 3 months, in addition to ongoing standard cytoreductive therapy. Self-injection or home-nurse administration; adherence tracked via injection diary. |
|
Geen tussenkomst: Cytoreductive therapy alone
Standard cytoreductive therapy continued alone, with no additional study treatment (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. No Month 1 visit. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in serum calprotectin levels
Tijdsspanne: Baseline and Month 3
|
Calprotectin levels are measured on serum samples by centralized analysis (µg/mL) |
Baseline and Month 3
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Improvement (yes/no) of the response status between baseline and month 3.
Tijdsspanne: Month 3
|
Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013). |
Month 3
|
|
Improvement (yes/no) of the response status between baseline and month 6.
Tijdsspanne: Month 6
|
Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013). |
Month 6
|
|
Improvement (yes/no) of the response status between month 3 and month 6.
Tijdsspanne: Month 6
|
Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013). |
Month 6
|
|
Hemoglobin count
Tijdsspanne: Baseline
|
Measurement of Hemoglobin in g/dL |
Baseline
|
|
Hematocrit count
Tijdsspanne: Baseline
|
Measurement of Hematocrit in % |
Baseline
|
|
White blood cell count
Tijdsspanne: Baseline
|
Measurement of WBC in G/L |
Baseline
|
|
Platelet cell count
Tijdsspanne: Baseline
|
Measurement of Platelets in G/L |
Baseline
|
|
Hemoglobin count
Tijdsspanne: Month 3
|
Measurement of Hemoglobin in g/dL |
Month 3
|
|
Hematocrit count
Tijdsspanne: Month 3
|
Measurement of Hematocrit in % |
Month 3
|
|
White blood cell count
Tijdsspanne: Month 3
|
Measurement of WBC in G/L |
Month 3
|
|
Platelet cell count
Tijdsspanne: Month 3
|
Measurement of Platelets in G/L |
Month 3
|
|
Hemoglobin count
Tijdsspanne: Month 6
|
Measurement of Hemoglobin in g/dL |
Month 6
|
|
Hematocrit count
Tijdsspanne: Month 6
|
Measurement of Hematocrit in % |
Month 6
|
|
White blood cell count
Tijdsspanne: Month 6
|
Measurement of WBC in G/L |
Month 6
|
|
Platelet cell count
Tijdsspanne: Month 6
|
Measurement of Platelets in G/L |
Month 6
|
|
Treatment-related adverse event for experimental group
Tijdsspanne: Month 1
|
A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria). |
Month 1
|
|
Treatment-related adverse event for experimental group
Tijdsspanne: Month 3
|
A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria). |
Month 3
|
|
Treatment-related adverse event for experimental group
Tijdsspanne: Month 6
|
A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria). |
Month 6
|
|
Adherence to treatment regimen for experimental group
Tijdsspanne: Month 1
|
Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between baseline and month 1. Days with missing diary entries will be excluded from the calculation. |
Month 1
|
|
Adherence to treatment regimen for experimental group
Tijdsspanne: Month 2
|
Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between month 1 and month 2. Days with missing diary entries will be excluded from the calculation |
Month 2
|
|
Adherence to treatment regimen for experimental group
Tijdsspanne: Month 3
|
Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between month 2 and month 3. Days with missing diary entries will be excluded from the calculation. |
Month 3
|
|
QLQ-C30 Summary Score
Tijdsspanne: Baseline
|
The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome. |
Baseline
|
|
QLQ-C30 Summary Score
Tijdsspanne: Month 3
|
The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome. |
Month 3
|
|
QLQ-C30 Summary Score
Tijdsspanne: Month 6
|
The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome. |
Month 6
|
|
Global health status / QoL score
Tijdsspanne: Baseline
|
Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life. |
Baseline
|
|
Global health status / QoL score
Tijdsspanne: Month 3
|
Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life. |
Month 3
|
|
Global health status / QoL score
Tijdsspanne: Month 6
|
Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life. |
Month 6
|
|
Patient-reported symptom severity over the previous 4 weeks for pruritus
Tijdsspanne: Baseline
|
Defined as the score on a 10-point Visual Analog Scale |
Baseline
|
|
Patient-reported symptom severity over the previous 4 weeks for fever
Tijdsspanne: Baseline
|
Defined as the score on a 10-point Visual Analog Scale |
Baseline
|
|
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Tijdsspanne: Baseline
|
Defined as the score on a 10-point Visual Analog Scale |
Baseline
|
|
Patient-reported symptom severity over the previous 4 weeks for pruritus
Tijdsspanne: Month 3
|
Defined as the score on a 10-point Visual Analog Scale |
Month 3
|
|
Patient-reported symptom severity over the previous 4 weeks for fever
Tijdsspanne: Month 3
|
Defined as the score on a 10-point Visual Analog Scale |
Month 3
|
|
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Tijdsspanne: Month 3
|
Defined as the score on a 10-point Visual Analog Scale |
Month 3
|
|
Patient-reported symptom severity over the previous 4 weeks for pruritus
Tijdsspanne: Month 6
|
Defined as the score on a 10-point Visual Analog Scale |
Month 6
|
|
Patient-reported symptom severity over the previous 4 weeks for fever
Tijdsspanne: Month 6
|
Defined as the score on a 10-point Visual Analog Scale |
Month 6
|
|
Patient-reported symptom severity over the previous 4 weeks for fever night sweats
Tijdsspanne: Month 6
|
Defined as the score on a 10-point Visual Analog Scale |
Month 6
|
|
Inflammatory biological profile
Tijdsspanne: Baseline
|
Measurement of IL-1β cytokines in pg/mL. |
Baseline
|
|
Inflammatory biological profile
Tijdsspanne: Month 3
|
Measurement of IL-1β cytokines in pg/mL. |
Month 3
|
|
Inflammatory biological profile
Tijdsspanne: Month 6
|
Measurement of IL-1β cytokines in pg/mL. |
Month 6
|
|
Inflammatory biological profile
Tijdsspanne: Baseline
|
Measurement of IL-6 cytokines in pg/mL. |
Baseline
|
|
Inflammatory biological profile
Tijdsspanne: Month 3
|
Measurement of IL-6 cytokines in pg/mL. |
Month 3
|
|
Inflammatory biological profile
Tijdsspanne: Month 6
|
Measurement of IL-6 cytokines in pg/mL. |
Month 6
|
|
Inflammatory biological profile
Tijdsspanne: Baseline
|
Measurement of IL-8 cytokines in pg/mL. |
Baseline
|
|
Inflammatory biological profile
Tijdsspanne: Month 3
|
Measurement of IL-8 cytokines in pg/mL. |
Month 3
|
|
Inflammatory biological profile
Tijdsspanne: Month 6
|
Measurement of IL-8 cytokines in pg/mL. |
Month 6
|
|
Inflammatory biological profile
Tijdsspanne: Baseline
|
Measurement of MIP-1β cytokines in pg/mL. |
Baseline
|
|
Inflammatory biological profile
Tijdsspanne: Month 3
|
Measurement of MIP-1β cytokines in pg/mL. |
Month 3
|
|
Inflammatory biological profile
Tijdsspanne: Month 6
|
Measurement of MIP-1β cytokines in pg/mL. |
Month 6
|
|
Inflammatory biological profile
Tijdsspanne: Baseline
|
Measurement of TNF-α cytokines in pg/mL. |
Baseline
|
|
Inflammatory biological profile
Tijdsspanne: Month 3
|
Measurement of TNF-α cytokines in pg/mL. |
Month 3
|
|
Inflammatory biological profile
Tijdsspanne: Month 6
|
Measurement of TNF-α cytokines in pg/mL. |
Month 6
|
|
Allele burden of the driver mutation
Tijdsspanne: Baseline
|
Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification. |
Baseline
|
|
Allele burden of the driver mutation
Tijdsspanne: Month 3
|
Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification. |
Month 3
|
|
Allele burden of the driver mutation
Tijdsspanne: Month 6
|
Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification. |
Month 6
|
|
Allele burden of the driver mutation
Tijdsspanne: Baseline
|
Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification. |
Baseline
|
|
Allele burden of the driver mutation
Tijdsspanne: Month 3
|
Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification. |
Month 3
|
|
Allele burden of the driver mutation
Tijdsspanne: Month 6
|
Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification. |
Month 6
|
|
Allele burden of the driver mutation
Tijdsspanne: Baseline
|
Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification. |
Baseline
|
|
Allele burden of the driver mutation
Tijdsspanne: Month 3
|
Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification. |
Month 3
|
|
Allele burden of the driver mutation
Tijdsspanne: Month 6
|
Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification. |
Month 6
|
|
Fibrosis markers
Tijdsspanne: Baseline
|
Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis. |
Baseline
|
|
Fibrosis markers
Tijdsspanne: Month 3
|
Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis. |
Month 3
|
|
Fibrosis markers
Tijdsspanne: Month 6
|
Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis. |
Month 6
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 29BRC25.0416
- 2025 (Subsidie/contract van de Amerikaanse NIH)
- 2025-523921-17-00 (Ctis)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .